









Markets
/
Stocks
/
nasdaq-plrx
/

Pliant Therapeutics Inc

PLRX

1.610USD

-0.060-3.59%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

98.83MMarket Cap

LossP/E TTM



Pliant Therapeutics Inc

1.610

-0.060-3.59%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pliant Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a good stock market performance, the company shows weak fundamentals and technicals, which don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pliant Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

113 / 159

Overall Ranking

323 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Hold

Current Rating

3.200

Target Price

+91.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pliant Therapeutics Inc Highlights

StrengthsRisks

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.47, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.45M shares, decreasing 41.00% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 73.49K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.11.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 5.80, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.80

Change



Financials

5.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Pliant Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.01, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.47, which is -28.56% below the recent high of -0.34 and -2501.92% above the recent low of -12.35.

Score

Industry at a Glance

Previous score

7.01

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Pliant Therapeutics Inc is 3.00, with a high of 4.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Hold

Current Rating

3.200

Target Price

+91.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Pliant Therapeutics Inc

PLRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 4.26, which is lower than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 1.89 and the support level at 1.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.35

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.023

Neutral

RSI(14)

47.527

Neutral

STOCH(KDJ)(9,3,3)

15.983

Sell

ATR(14)

0.139

Low Volatility

CCI(14)

-87.000

Neutral

Williams %R

79.070

Sell

TRIX(12,20)

0.558

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.668

Sell

MA10

1.729

Sell

MA20

1.656

Sell

MA50

1.604

Buy

MA100

1.525

Buy

MA200

2.268

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 85.44%, representing a quarter-over-quarter decrease of 16.25%. The largest institutional shareholder is Steven Cohen, holding a total of 3.76M shares, representing 6.13% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Tang Capital Management, LLC

6.00M

Deep Track Capital LP

3.95M

The Vanguard Group, Inc.

Star Investors

3.00M

-9.71%

Blue Owl Capital Holdings LP

2.97M

UBS Financial Services, Inc.

2.65M

+0.04%

Citadel Advisors LLC

2.36M

+3624360.00%

Woodline Partners LP

2.35M

-6.59%

Madison Avenue Partners LP

2.23M

+33.13%

Third Rock Ventures, LLC

2.13M

Morgan Stanley & Co. LLC

1.99M

+93.93%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.98, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.